David A. Siegel Intellia Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
314Shares Held
91.5MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$148 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$116 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$116 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$62 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$59.6 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $916M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...